Car T-Cell Therapy

Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.

A chimeric antigen receptor T-cell therapy induced high response rates across a range of B-cell malignancies, according to phase 1 study results presented at ASH Annual Meeting and Exposition.

Penn Medicine received a 7-year, $14 million grant from the NIH to use chimeric antigen receptor T-cell immunotherapies to match patients in need of kidney transplants, according to a press release.

The FDA cleared an investigational new drug application for P-MUC1C-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with locally advanced or metastatic epithelial-derived solid tumors.

In this video, Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center discusses three randomized trials testing CD19-directed autologous chimeric antigen receptor T-cell therapies against chemotherapy and autologous transplant in the second line setting for lymphoma, which were presented at ASH.

In this video, Rayne Rouce, MD, discusses the top chimeric antigen receptor T-cell therapy-related presentations at ASH.

In this video, Rayne Rouce, MD, discusses the top chimeric antigen receptor T-cell therapy-related presentations at ASH, including several presentations targeting T-cell malignancies, which she said is exciting.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology & cellular therapy at the Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses a presentation from his group at ASH on the association between CAR T-cells and the cytopenia that commonly occur after therapy.

In this video, Saad Usmani, MD, division chief of plasma cell disorders and director of clinical research in hematologic malignancies at Levine Cancer Institute/Atrium Health, offers insights regarding abstracts on developments in chimeric antigen receptor T-cell therapy at ASH Annual Meeting and Expo.